NeuroNOS Company Profile, Contacts & Intelligence

NeuroNOS Overview

NeuroNOS is pioneering a first-in-class therapy that targets the root biological causes of autism. Backed by two Nobel Laureates and granted FDA Orphan Drug Designation, we are developing a novel small molecule designed to restore brain function—not just manage symptoms. Our work is based on the groundbreaking discovery by Prof. Haitham Amal (Harvard/Boston Children’s), who uncovered the critical role of nitric oxide (NO) dysregulation in autism. This mechanism—now considered foundational in ASD research—involves oxidative and nitrosative stress, synaptic dysfunction, and disrupted brain metabolism. Our selective nNOS-targeted compound is engineered to correct this pathway. Led by research from MIT and Hebrew University, our preclinical data show near-complete restoration of behavioral and brain function in multiple ASD models. 🔹 FDA Orphan Drug Designation granted 🔹 First-in-human trials targeted for 2026 🔹 Strategic partnerships in progress We are proudly supported by Prof. Roger D. Kornberg (Nobel Laureate, Chemistry), Prof. Dan Shechtman (Nobel Laureate, Physics), and Prof. Amal as CSO. As we prepare for clinical trials, we welcome conversations with partners and investors who share our mission: to bring meaningful, mechanism-based therapies to individuals with autism—and ultimately, other brain disorders like Alzheimer's and glioblastoma. 🎥 Watch our story: https://youtu.be/DV9DNYzKSAI 📄 Publication: https://doi.org/10.1002/advs.202205783

Website

www.neuro-nos.com

Industry

Biotechnology Research

NAICS

Research and Development in Biotechnology (except Nanobiotechnology)

NeuroNOS Contact Intelligence

See which contact channels and departments are represented in the visible AeroLeads data.

NeuroNOS People & Org Chart Preview

Sample people records show job titles and whether email or phone data is available without exposing raw contact details.

Compare Similar Companies to NeuroNOS

Explore companies in related markets and compare their industry and employee estimates.